Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C

• Published in: Hepatology research Vol. 44; no. 14; pp. E447 - E454
• Main Authors: Nagaoki, Yuko, Imamura, Michio, Kawakami, Yoshiiku, Kan, Hiromi, Fujino, Hatsue, Fukuhara, Takayuki, Kobayashi, Tomoki, Ono, Atsushi, Nakahara, Takashi, Naeshiro, Noriaki, Urabe, Ayako, Yokoyama, Satoe, Miyaki, Daisuke, Murakami, Eisuke, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Aikata, Hiroshi, Takahashi, Shoichi, Hayes, C. Nelson, Ochi, Hidenori, Chayama, Kazuaki
• Format: Journal Article
• Language: English
• Published: Netherlands Blackwell Publishing Ltd 01.12.2014
• Subjects: chronic hepatitis C; inteferon lambda 4; rapid virological response; sustained virological response; telaprevir; inteferon lambda 4; rapid virological response; telaprevir; chronic hepatitis C; sustained virological response
• ISSN: 1386-6346; 1872-034X
• DOI: 10.1111/hepr.12336

Aim The predictive value of the recently identified interferon‐λ (IFNL)4 polymorphism on the outcome of telaprevir (TVR), pegylated interferon (PEG IFN) plus ribavirin (RBV) combination therapy for chronic hepatitis C is unknown. Methods We assessed predictive factors for sustained virological response (SVR) for TVR, PEG IFN plus RBV combination therapy in 283 genotype 1 chronic hepatitis C patients. IFNL4 polymorphism ss469415590 was analyzed by Invader assay. Results SVR rates for patients with IFNL4 TT/TT genotype were significantly higher than for those with the IFNL4 TT/ΔG or ΔG/ΔG genotypes (93% and 59%, respectively, P < 0.0001). In a multivariate regression analysis, prior treatment history (treatment‐naïve patients or patients who relapsed during prior treatment) (odds ratio [OR], 2.385; P = 0.028), rapid virological response (OR, 6.800; P < 0.0001) and ss469415590 TT/TT genotype (OR, 8.064; P < 0.0001) were identified as significant independent predictors for SVR. In patients with IFNL4 TT/ΔG or ΔG/ΔG genotypes, SVR rates for non‐RVR patients were significantly lower than RVR patients (22% and 75%, respectively, P < 0.0001). Conclusion Analysis of IFNL4 polymorphism is a valuable predictor in patients receiving TVR triple therapy.